Strategy
We focus on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide flexible, long term capital to help accelerate their ideas into important new treatments for patients.
Investment criteria
We are science led investors, focusing on innovative technologies in areas of high unmet need. Unconstrained by institution, geography or stage of company development we have the ability to source the best life science innovation without restriction.
Focus
Novel therapeutics with first or best in class approach. We focus on on investing in high impact science, with the potential to dramatically improve outcomes for patients.
Source
Unconstrained approach to sourcing innovation. Arix benefits from extensive global networks including deep venture capital and biotech networks, pharmaceutical and academic partners
Geography
Extensive global networks provide easy access to the best life science innovation across the globe
Development Stage
Flexible to the point of entry. We invest in seed stage companies, preclinical and clinical stage assets; private or public